In This Issue:

- E&C continues to push for bipartisan efforts to improve drug pipeline

- Implementation of the Affordable Care Act

- Other Federal Regulatory Initiatives

- Other Health Care News

- Upcoming Hearings and Markups

- Excerpt from E&C continues to push for bipartisan efforts to improve drug pipeline:

This week, the House Energy and Commerce health subcommittee continues an effort launched in May to find potential common ground that legislators can coalesce around to improve the drug pipeline from discovery to development to delivery. On Wednesday, July 9th, the panel will examine opportunities to modernize clinical trials and accelerate the development of new cures and treatments. On Friday, July 11, the committee will solicit feedback from patients on how to expedite the drug discovery, development, and delivery process.

Please see full issue below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

CDC
CMS
HHS
NIH

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz Levin - Health Law & Policy Matters | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.
×
Loading...
×